Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 10
2013 10
2014 17
2015 8
2016 8
2017 8
2018 12
2019 8
2020 10
2021 14
2022 12
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Burkitt's Lymphoma.
Roschewski M, Staudt LM, Wilson WH. Roschewski M, et al. N Engl J Med. 2022 Sep 22;387(12):1111-1122. doi: 10.1056/NEJMra2025746. N Engl J Med. 2022. PMID: 36129999 Review. No abstract available.
Burkitt lymphoma.
López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, Orem J, Rochford R, Roschewski M, Siebert R. López C, et al. Among authors: roschewski m. Nat Rev Dis Primers. 2022 Dec 15;8(1):78. doi: 10.1038/s41572-022-00404-3. Nat Rev Dis Primers. 2022. PMID: 36522349 Review.
Circulating Tumor DNA in Lymphoma: Principles and Future Directions.
Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Roschewski M, et al. Blood Cancer Discov. 2022 Jan;3(1):5-15. doi: 10.1158/2643-3230.BCD-21-0029. Epub 2021 Sep 30. Blood Cancer Discov. 2022. PMID: 35015693 Free PMC article. Review.
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dunleavy K, et al. Among authors: roschewski m. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. Lancet Haematol. 2018. PMID: 30501868 Free PMC article. Clinical Trial.
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Roschewski M, et al. J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303. Epub 2020 May 26. J Clin Oncol. 2020. PMID: 32453640 Free PMC article.
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: roschewski m. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Kurtz DM, et al. Among authors: roschewski m. Nat Biotechnol. 2021 Dec;39(12):1537-1547. doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22. Nat Biotechnol. 2021. PMID: 34294911 Free PMC article.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM. Advani R, et al. Among authors: roschewski m. N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315. N Engl J Med. 2018. PMID: 30380386 Free PMC article. Clinical Trial.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Lionakis MS, et al. Among authors: roschewski m. Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25. Cancer Cell. 2017. PMID: 28552327 Free PMC article.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Frigault MJ, et al. Among authors: roschewski m. Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738. Blood. 2022. PMID: 35167655 Free PMC article. Clinical Trial.
113 results